My Top Five Highlights in Lung Cancer from 2014


An annual tradition is a reflection on the key developments in the field over the past year. This year saw some major advances, with several of the biggest changes bubbling just below the surface and about to really break out in 2015.  So without further adieu, here's my list.

For those who wish to access the pdf, it's here: Top 5 Highlights in Lung Cancer 2014

Agree? Disagree? What's highest on your wish list for 2015?

EGFR T790M as a Clinical Biomarker in Lung Cancer


EGFR T790M is a point mutation in the EGFR gene that is associated with resistance to epidermal growth factor receptor (EGFR) kinase inhibitors like erlotinib and gefitinib. Since its initial discovery in 2005, the T790M mutation has been the subject of much research aiming to better understand drug resistance in non-small cell lung cancer (NSCLC). However, the role of T790M as a biomarker for the clinical care of lung cancer patients over the same time period has been less clear.

Subscribe to T790M